Zomedica CORP Form 4 insider transactions

Director Rodney James Williams purchased 100,000 shares of Zomedica Corp. at $0.069 per share, increasing his direct holdings.

Zomedica's Chief Financial Officer, Scott Jordan, recently purchased 300,000 shares of the company's common stock at a price of $0.062 per share.

Director Jeffrey M. Rowe increases his indirect holdings in Zomedica Corp. through multiple purchases via a living trust.

Director Christopher MacLeod purchased 143,000 shares of Zomedica Corp. common stock at $0.059 per share on March 17, 2025.

Director Johnny D. Powers increased his holdings in Zomedica Corp. (ZOM) through a series of open market purchases on March 17, 2025, totaling 500,000 shares.

Zomedica Corp. CEO Larry Heaton II reports purchasing shares of common stock at prices between $0.054 and $0.06, increasing his direct holdings.

Zomedica's COO, Tony Blair, reports the acquisition and disposal of company stock on March 17, 2025.

Russell Kevin Klass, Sr Vice President of Sales at Zomedica Corp., reports acquiring 699,980 shares of common stock at $0.07 per share on March 17, 2025.

Director Rodney Williams reports purchasing 100,000 shares of Zomedica Corp. common stock at $0.069 per share.

Russell Kevin Klass, Sr. Vice President of Sales at Zomedica Corp., acquired 200,000 stock options on February 21, 2025.

Zomedica's Chief Financial Officer, Scott Jordan, was granted 5 million stock options on January 1, 2025.

A Zomedica Corp. director, Rodney James Williams, amended a previous filing to correct the recipient name associated with a grant of 1,975,033 stock appreciation rights.

Zomedica Corp. director Johnny D. Powers acquired 1,975,033 stock appreciation rights on November 11, 2024.

Zomedica Corp. director Sean Whelan acquired 1,975,033 stock appreciation rights on November 11, 2024.

Zomedica Corp. director Jeffrey M. Rowe acquired 2,126,959 stock appreciation rights on November 11, 2024.

Zomedica Corp. director Johnny D. Powers acquired 1,823,107 stock appreciation rights on November 11, 2024.

Zomedica Corp. director Pamela Nichols acquired 1,975,033 stock appreciation rights on November 11, 2024.

Zomedica Corp. director Christopher MacLeod acquired 1,823,107 stock appreciation rights on November 11, 2024.

Zomedica Corp. director Robert Cohen acquired 1,823,107 stock appreciation rights on November 11, 2024.

Zomedica Corp.'s General Counsel, Karen DeHaan-Fullerton, has been granted 500,000 stock options.

Zomedica Corp.'s Chief Operating Officer, Anthony K. Blair, has acquired 400,000 stock options with a strike price of $0.13, vesting over four years.

Zomedica's Chief Operating Officer, Anthony Blair, acquired 150,000 shares and disposed of 400,000 shares of common stock in recent transactions.

Director Johnny D. Powers of Zomedica Corp. reports purchasing 100,000 shares of common stock at $0.121 per share on November 11, 2024.

Zomedica Corp. CEO Larry Heaton II reported the sale of 100,000 shares of common stock on November 11, 2024.

Russell Kevin Klass, Vice President of Sales at Zomedica Corp., reports acquiring 500,000 shares of common stock through open market purchases.

Zomedica Corp. CEO Larry Heaton II reports the acquisition and disposition of common stock on September 5, 2024.

Director Johnny D. Powers of Zomedica Corp. reports the acquisition of 100,000 shares of common stock at $0.129 per share on August 28, 2024.

Zomedica Corp. COO Tony Blair reports the acquisition and disposal of common stock on August 20, 2024.

Russell Kevin Klass, Vice President of Sales at Zomedica Corp., reports the sale of 299,993 shares of common stock at a weighted average price of $0.1551.

Russell Kevin Klass, Vice President of Sales at Zomedica Corp., reports purchasing common stock in two transactions on June 10 and June 11, 2024.